Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their target price on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Stock Up 3.1 %

Shares of EVGN stock opened at $1.67 on Tuesday. Evogene has a twelve month low of $1.44 and a twelve month high of $10.40. The stock’s fifty day simple moving average is $2.37 and its 200 day simple moving average is $4.40. The firm has a market capitalization of $8.96 million, a P/E ratio of -0.37 and a beta of 1.43.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new position in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.